Democratising access to essential biological medicines.
Over the past two decades, biotechnology innovation has transformed treatment outcomes for many life threatening diseases.
Yet access to biological medicines remains profoundly unequal: over 80% of biological medicines are available to less than 15% of the global population, with affordability being the single greatest barrier.
Ena Biologics is addressing this gap through manufacturing innovation - enabling a step-change reduction in the cost of essential biological medicines while maintaining uncompromising quality.
Strategic Principles
Three strategic principles are the foundation for Ena Biologics becoming a sustainable leader in biosimilars, providing affordable essential biologic medicines globally.
Technology
Leadership
Highly automated, small-footprint manufacturing designed for cost efficiency, reproducibility, and rapid deployment.
Cutting-edge analytics and release platforms ensuring biosimilarity, consistency, and global regulatory compliance.
Uncompromising
Quality
Resilient
Scalability
Decentralised manufacturing and supply networks designed to enhance resilience, reduce logistics burden, and sustain long-term cost leadership.
People
Our team brings together leaders in company creation, biologics development, advanced manufacturing, and global commercialisation - with experience spanning venture creation through to large-scale product launch.
Charlotte
Casebourne Stock
CO - CEO
Harald
Casebourne Stock
CO - CEO
Greta
Mistinaite
Head of Program Management
Einat
Frydman
General Manager, UK
Partners
Company creator and shaper Yarvie is working together with manufacturing technology innovator Cell and Gene Therapy Catapult to establish Ena Biologics as a biosimilars leader, democratising access to essential biological medicines.
